Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

Optimal oral anticoagulant therapy in patients with mechanical heart valves

Article Abstract:

The best dosage of anticlotting drugs for patients with artificial heart valves may be one that produces an international normalized ratio (INR) of coagulation between 2.5 and 4.9. Researchers analyzed the medical records of 1608 patients with artificial heart valves. The patients received coumarin derivative anticlotting drugs. The total follow-up time was 6475 patient-years, at an average of 4 years per patient. For patients with a INR between 2.5 and 4.9 the rate of blood vessel blockage or bleeding was about 2 per 100 patient-years. At INR levels below 2.5 the incidence of clotting increased sharply. At INR levels above 4.9 the incidence of hemorrhages increased sharply. An INR between 3.0 and 4.0 may be the best target in administering the drugs.

Author: Vandenbroucke, J.P., Cannegieter, S.C., Rosendaal, F.R., Wintzen, A.R., Meer, F.J.M van der, Briet, E.
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 1995
Prognosis, Heart valve prosthesis, Artificial heart valves

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Care of patients receiving long-term anticoagulant therapy

Article Abstract:

Patients with artificial heart valves, mitral valve disease, atrial fibrillation, and venous thromboembolism should be treated with long-term anticoagulants to prevent abnormal blood clotting. They should be given a dose to produce an international normalized ratio (INR) of 2 to 3. A monthly prothrombin time test can be used to adjust the dose and vitamin K can be given if necessary to reduce the risk of excessive bleeding.

Author: Schulman, Sam
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2003
Prevention, Thrombosis, Blood clot, Hypercoagulation

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


D-dimer testing to determine the duration of anticoagulation therapy

Article Abstract:

D-dimer levels are tested to assess the optimal duration of oral anticoagulation in patients with idiopathic venous thromboembolism. It is evaluated that patients with abnormal D-dimer have a recurrence of venous thromboembolism after the discontinuation of anticoagulation but reduces on its resumption whereas for patients with normal D-dimer level, the optimal course of anticoagulation is not clearly established.

Author: Palareti, Gualtiero; Cosmi, Benilde; Legnani, Cristina, Tosetto, Alberto; Brusi, Carlotta; Lorio, Alfonso, Pengo, Vittorio; Ghirarduzzi, Angelo, Lensing, Anthonie W.A.; Tripodi, Armando, Pattacini, Corrado; Testa, Sophie
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2006
Drug therapy, Thrombophlebitis, Clinical report

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Anticoagulants (Medicine), Anticoagulants, Dosage and administration
Similar abstracts:
  • Abstracts: Cesarean section by local anesthesia in patients with familial dysautonomia
  • Abstracts: Intravenous therapy at home. The value of nursing
  • Abstracts: Paricalcitol as compared with calcitriol in patients undergoing hemodialysis. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy
  • Abstracts: Adolescents' perceptions of factors affecting their decisions to seek health care. Screening for risk of persistent posttraumatic stress in injured children and their parents
  • Abstracts: Use of health services by African-American children with asthma on Medicaid. Provision of pneumococcal prophylaxis for publicly insured children with sickle cell disease
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.